The Precision Oncology Market Forecast projects substantial, stable double-digit growth, with the global market size (estimated around $115 Billion to $126 Billion USD in 2024) expected to reach approximately $190 Billion to $202 Billion by 2030. This growth translates to a robust Compound Annual Growth Rate (CAGR) generally in the range of 8.0% to 9.9% from 2025 to 2030. This strong trajectory reflects the industry's successful shift from mass-market chemotherapy to highly targeted, molecularly driven treatment.

To ensure long-term visibility, there is little bit change in content from now. A core assumption underpinning the Precision Oncology Market Forecast is the accelerated adoption of Next-Generation Sequencing (NGS) and Liquid Biopsy as standard-of-care diagnostics. The forecast anticipates significant demand spikes related to new Regulatory Approvals for biomarker-defined targeted therapies, which automatically mandate the use of companion diagnostics. Furthermore, the increasing global prevalence of cancer and the successful demonstration of improved patient survival and quality of life via personalized treatment will continue to anchor the strong, upward trajectory projected by the Precision Oncology Market Forecast. [Precision Oncology Market Forecast]